CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized...
Phase 3
Seattle, Washington, United States and 18 other locations
will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple...
Phase 1
Seattle, Washington, United States and 20 other locations
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofat...
Phase 4
Seattle, Washington, United States and 36 other locations
This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early...
Phase 4
Kirkland, Washington, United States and 35 other locations
A single arm study evaluating the continued efficacy, safety and tolerability of ofatumumab in patients with relapsing multiple sclerosis...
Phase 3
Seattle, Washington, United States and 20 other locations
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...
Phase 3
Seattle, Washington, United States and 220 other locations
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...
Phase 3
Seattle, Washington, United States and 230 other locations
for the overall conduct of the study at the site, confirmation of subject eligibility, routine study subject clinical management including for MS...
Phase 3
Seattle, Washington, United States and 60 other locations
) neo-antigen in subjects with relapsing multiple sclerosis (RMS)....
Phase 3
Kirkland, Washington, United States and 301 other locations
Clinical trials
Research sites
Resources
Legal